Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 14;30(42):4591-4596.
doi: 10.3748/wjg.v30.i42.4591.

Helicobacter pylori, esophageal precancerous lesions, and proton pump inhibitor overuse

Feng Zhang  1   2 , Hang Zhang  1   2 , Yan-Miao Liu  3 , Fu-Shan Tang  1   2   4
Affiliations
Review

Helicobacter pylori, esophageal precancerous lesions, and proton pump inhibitor overuse

Feng Zhang et al. World J Gastroenterol. .

Abstract

This article reviews the cohort study published in the World Journal of Gastroenterology, which reported low rates of Helicobacter pylori (H. pylori) infection among esophageal cancer (EC) patients, coupled with proton pump inhibitor (PPI) overuse. These findings suggest a potential protective role of H. pylori against EC and indicate a possible association between PPI use and increased cancer risk. In light of these findings, our article examines the complex relationship between H. pylori and esophageal precancerous lesions, exploring the potential underlying mechanisms. We also address growing concerns regarding PPI overuse, including its potential effects on cancer therapy efficacy and the risk of drug interactions. Ultimately, this article highlights the urgent need for further research to evaluate the safety and efficacy of PPIs in cancer patients and to better understand their broader implications.

Keywords: Cancer; Drug abuse; Esophageal carcinoma; Esophageal precancerous lesions; Helicobacter pylori; Proton pump inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.

References

    1. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21:7933–7943. - PMC - PubMed
    1. Fabian T, Leung A. Epidemiology of Barrett's Esophagus and Esophageal Carcinoma. Surg Clin North Am. 2021;101:381–389. - PubMed
    1. López-Gómez M, Morales M, Fuerte R, Muñoz M, Delgado-López PD, Gómez-Cerezo JF, Casado E. Prevalence of Helicobacter pylori infection among patients with esophageal carcinoma. World J Gastroenterol. 2024;30:3479–3487. - PMC - PubMed
    1. Böhme F, Racz K, Sebesta C Jr, Sebesta C. [Esophageal Cancer] Wien Med Wochenschr. 2023;173:209–215. - PubMed
    1. Ma S, Guo X, Wang C, Yin Y, Xu G, Chen H, Qi X. Association of Barrett's esophagus with Helicobacter pylori infection: a meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223221117971. - PMC - PubMed

MeSH terms

Substances